Mayne Pharma adds generic Cordarone dosage strength
Mayne Pharma has launched its 200-mg generic Cordarone tablets (amiodarone). The drug is indicated to treat life-threatening recurrent ventricular arrhythmia.
The 200-mg generic Cordarone joins the 100- and 400-mg strength tablets that the Greenville, N.C.-based company had previously launched. The product had U.S. sales of roughly $22 million for the 12 months ended January 2018.
The latest launch is being manufactured at Mayne Pharma’s new manufacturing facility in Greenville that was completed recently, and which CEO Scott Richards said has potential to improve the company’s manufacturing capabilities.
“This new solid oral-dose manufacturing facility quadruples the company’s U.S. manufacturing capacity to well over 1 billion doses annually, and importantly introduces significant capacity to manufacture potent compounds and new capability to manufacture modified-release bead/pellet products,” Richards said.
The 200-mg generic Cordarone joins the 100- and 400-mg strength tablets that the Greenville, N.C.-based company had previously launched. The product had U.S. sales of roughly $22 million for the 12 months ended January 2018.
The latest launch is being manufactured at Mayne Pharma’s new manufacturing facility in Greenville that was completed recently, and which CEO Scott Richards said has potential to improve the company’s manufacturing capabilities.
“This new solid oral-dose manufacturing facility quadruples the company’s U.S. manufacturing capacity to well over 1 billion doses annually, and importantly introduces significant capacity to manufacture potent compounds and new capability to manufacture modified-release bead/pellet products,” Richards said.